Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Department of Genetics, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 10/2001; 98(19):10869-74. DOI: 10.1073/pnas.191367098
Source: PubMed

ABSTRACT The purpose of this study was to classify breast carcinomas based on variations in gene expression patterns derived from cDNA microarrays and to correlate tumor characteristics to clinical outcome. A total of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four normal breast tissues were analyzed by hierarchical clustering. As reported previously, the cancers could be classified into a basal epithelial-like group, an ERBB2-overexpressing group and a normal breast-like group based on variations in gene expression. A novel finding was that the previously characterized luminal epithelial/estrogen receptor-positive group could be divided into at least two subgroups, each with a distinctive expression profile. These subtypes proved to be reasonably robust by clustering using two different gene sets: first, a set of 456 cDNA clones previously selected to reflect intrinsic properties of the tumors and, second, a gene set that highly correlated with patient outcome. Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A large number of etiological factors and the complexity of breast cancers present challenges for prevention and treatment. Recently, the emergence of microRNAs (miRNAs) as cancer biomarkers has added an extra dimension to the ‘molecular signatures’ of breast cancer. Bioinformatic analyses indicate that each miRNA can regulate hundreds of target genes and could serve functionally as ‘oncogenes’ or ‘tumour suppressor’ genes, and co-ordinate multiple cellular processes relevant to cancer progression. A number of studies have shown that miRNAs play important roles in breast tumorigenesis, metastasis, proliferation and differentiation of breast cancer cells. This review provides a comprehensive overview of miRNAs with established functional relevance in breast cancer, their established target genes and resulting cellular phenotype. The role and application of circulating miRNAs in breast cancer is also discussed. Furthermore, we summarize the role of miRNAs in the hallmarks of breast cancer, as well as the possibility of using miRNAs as potential biomarkers for detection of breast cancer.
    Biological Reviews 01/2015; · 9.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is a heterogeneous disease classified by variations in gene expression, and as such, concepts regarding treatment recommendations according to molecular classification are being explored. Retrospective data from hypothesis-generating subset analyses of adjuvant clinical trials have shown that patients with lower oestrogen receptor (ER) expression are more likely to benefit from adjuvant chemotherapy compared with patients who have intermediate or high ER expression. In addition, greater benefit is obtained from increasing the dose density of chemotherapy for ER-negative versus ER-positive disease, although some ER-positive patients do benefit from more aggressive chemotherapy. A high research priority is to identify those ER-positive patients who will benefit from multi-agent chemotherapy. Subset analyses have also shown that patients with progesterone receptor (PR)-negative disease may benefit from taxane-based chemotherapy, regardless of ER status. Furthermore, adjuvant trastuzumab should be considered in human epidermal growth factor receptor-2-positive patients who have a moderate/high risk of recurrence. These molecular classifications are being used to design clinical trials to enable adjuvant treatment recommendations to be made based not only on prognostic factors but also on predictive factors for benefit. In future, therapies will increasingly target particular molecular subsets and, as a result, become more effective.
    EJC Supplements 01/2007; 5(1):3-10. · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The p53 protein family, comprising p53, p63 and p73, is primarily involved in preserving genome integrity and preventing tumor onset, and also affects a range of physiological processes. Signal-dependent modifications of its members and of other pathway components provide cells with a sophisticated code to transduce a variety of stress signaling into appropriate responses. TP53 mutations are highly frequent in cancer and lead to the expression of mutant p53 proteins that are endowed with oncogenic activities and sensitive to stress signaling. p53 family proteins have unique structural and functional plasticity, and here we discuss the relevance of prolyl-isomerization to actively shape these features. The anti-proliferative functions of the p53 family are carefully activated upon severe stress and this involves the interaction with prolyl-isomerases. In particular, stress-induced stabilization of p53, activation of its transcriptional control over arrest- and cell death-related target genes and of its mitochondrial apoptotic function, as well as certain p63 and p73 functions, all require phosphorylation of specific S/T-P motifs and their subsequent isomerization by the prolyl-isomerase Pin1. While these functions of p53 counteract tumorigenesis, under some circumstances their activation by prolyl-isomerases may have negative repercussions (e.g. tissue damage induced by anticancer therapies and ischemia-reperfusion, neurodegeneration). Moreover, elevated Pin1 levels in tumor cells may transduce deregulated phosphorylation signaling into activation of mutant p53 oncogenic functions. The complex repertoire of biological outcomes induced by p53 finds mechanistic explanations, at least in part, in the association between PPIases and the p53 pathway. This article is part of a Special Issue entitled Proline-directed Foldases: Cell Signaling Catalysts and Drug Targets. Copyright © 2015. Published by Elsevier B.V.
    Biochimica et biophysica acta. 01/2015;


Available from
Jun 3, 2014